Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Isocitrate Dehydrogenase (IDH) Inhibitors Market Revenue Growth On Track For A 26.6% CAGR Through 2030
The market size for isocitrate dehydrogenase (idh) inhibitors has experienced significant growth in recent years. It is projected to expand from $2.46 billion in 2025 to $3.13 billion in 2026, achieving a compound annual growth rate (CAGR) of 26.8%. This historical growth can be attributed to several factors, including advancements in cancer genomics research, the urgent unmet needs in oncology, the emergence of mutation-driven drug discovery, broader hospital oncology adoption, and an increase in clinical trial expansion.
The isocitrate dehydrogenase (idh) inhibitors market size is anticipated to experience substantial growth over the next few years, with projections indicating it will expand to $8.02 billion in 2030 at a compound annual growth rate (CAGR) of 26.6%. This expected expansion during the forecast period is driven by progress in precision medicine, the rise of biomarker-driven oncology care, robust rare cancer drug pipelines, the development of combination cancer therapies, and regulatory backing for targeted drugs. Significant trends in the coming period encompass the broadening of targeted oncology therapies, increased drug development based on genetic mutations, an intensifying focus on treatments for rare cancers, the growing utilization of precision oncology diagnostics, and ongoing advancements in small molecule cancer inhibitors.
Get A Free Sample Report With In-Depth Market Insights:
Isocitrate Dehydrogenase (IDH) Inhibitors Market Development Factors: What’s Supporting Demand?
The rising incidence of acute myeloid leukemia is anticipated to fuel the expansion of the isocitrate dehydrogenase (IDH) inhibitors market. Acute myeloid leukemia (AML) is characterized as a rapidly progressing cancer affecting the blood and bone marrow, marked by the swift generation of abnormal white blood cells that impede normal blood cell formation. This increased occurrence of AML is linked to an expanding aging population, as older individuals face a heightened risk of developing this aggressive blood cancer due to age-related changes in their bone marrow and immune system. Isocitrate dehydrogenase (IDH) inhibitors effectively treat acute myeloid leukemia by blocking mutant IDH enzymes, which helps restore typical blood cell development and decelerates the proliferation of leukemia cells. For instance, in February 2023, a report from the Leukaemia Foundation, an Australia-based non-profit organization, indicated that between 2022 and 2035, more than 7,000 children, 6,000 young adults, and 108,000 adults aged 25–65 are expected to be diagnosed with various blood cancers, primarily acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), and non-Hodgkin lymphoma (NHL). Consequently, the growing frequency of acute myeloid leukemia is projected to propel the growth of the isocitrate dehydrogenase (IDH) inhibitors market.
Isocitrate Dehydrogenase (IDH) Inhibitors Market Segment Analysis And Revenue Potential
The isocitrate dehydrogenase (idh) inhibitors market covered in this report is segmented –
1) By Type: IDH1 Mutant Medullary Malignant Tumor, IDH2 Mutant Medullary Malignant Tumor, Other Types
2) By Molecule Type: Monoclonal Antibodies, Peptides, Small Molecules, Other Molecule Types
3) By Route Of Administration: Oral, Parenteral, Subcutaneous, Topical
4) By Application: FLT3 Inhibitor, DH Inhibitor, Hedgehog Pathway Inhibitor, Other Applications
Subsegments:
1) By IDH1 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Glioma Or Glioblastoma, Cholangiocarcinoma, Chondrosarcoma
2) By IDH2 Mutant Medullary Malignant Tumor: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Angioimmunoblastic T-Cell Lymphoma (AITL)
3) By Other Types: Solid Tumors With IDH Mutations, Metastatic Cancers With IDH Alterations, Experimental Or Off-Label Uses In Rare Cancers
Isocitrate Dehydrogenase (IDH) Inhibitors Market Transformation Trends: What Innovations Are Driving Change?
Key companies operating in the isocitrate dehydrogenase (IDH) inhibitors market are heavily focused on securing regulatory approvals. This strategic emphasis aims to broaden the clinical applications of their therapies, accelerate their entry into the market, and achieve a competitive advantage in the treatment of IDH-mutant cancers. Regulatory approvals are formal permissions granted by health authorities, enabling a drug to be marketed and utilized after its safety and effectiveness have been confirmed. For instance, in August 2024, Servier Laboratoires, a pharmaceutical company based in France, received FDA approval for VORANIGO (vorasidenib) tablets. This approval designates it as the first targeted therapy for patients diagnosed with Grade 2 IDH-mutant glioma, including astrocytoma and oligodendroglioma with IDH1 or IDH2 mutations. This oral treatment significantly extends progression-free survival, a finding from the Phase 3 INDIGO trial, where patients experienced a median progression-free survival of 27.7 months compared to 11.1 months for the placebo group. VORANIGO provides a convenient and well-tolerated treatment choice with manageable side effects, representing a major therapeutic advancement for patients who previously had limited options.
Isocitrate Dehydrogenase (IDH) Inhibitors Market Key Players Shaping Industry Direction
Major companies operating in the isocitrate dehydrogenase (idh) inhibitors market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Eli Lilly and Company, Daiichi Sankyo Company Limited, Les Laboratoires Servier, Evotec SE, HUTCHMED (China) Limited, Rigel Pharmaceuticals Inc., CStone Pharmaceuticals, Forma Therapeutics Holdings Inc., Philogen S.p.A., Kura Oncology Inc., Agios Pharmaceuticals Inc., Adooq Bioscience LLC, Taiho Pharmaceutical Co. Ltd., Celgene Corporation, Focus Biomolecules LLC, InvivoChem LLC
View The Full Isocitrate Dehydrogenase (IDH) Inhibitors Market Report:
Isocitrate Dehydrogenase (IDH) Inhibitors Market Regional Analysis And Leading Geography
North America was the largest region in the isocitrate dehydrogenase (IDH) inhibitors market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the isocitrate dehydrogenase (idh) inhibitors market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model